Choline metabolism drives metastasis in BRCA1-deficient ovarian cancers by activating FAM3C

Choline metabolism (via the CTL4 transporter and *FAM3C* stabilization) promotes metastasis of *BRCA1*-deficient ovarian cancers

This mechanistic study shows that BRCA1 deficiency strongly increases choline metabolism in ovarian cancer, beyond its canonical role in DNA repair. Loss of BRCA1 relieves the epigenetic repression (EZH2/H3K27Me3) of the choline transporter CTL4, whose overexpression stabilizes the epithelial-to-mesenchymal transition inducer FAM3C and promotes invasion. A CTL4 inhibitor (DT-13) effectively suppresses metastasis in BRCA1-deficient models. CTL4 thus emerges as a therapeutic target specific to metastatic BRCA1-mutated ovarian cancers.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

An elegant fundamental study opening a therapeutic avenue beyond PARP inhibitors for BRCA1-deficient tumors, exploiting a metabolic vulnerability. Clinical impact remains preclinical at this stage (cell/animal models), but demonstrating an actionable target with an available inhibitor is worth following. For genetic counseling, the main lesson is the breadth of BRCA1's non-canonical functions.